Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

Published:2020-06-01 Issue:6 Volume:6 Page:856
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Arrieta Oscar¹,Barrón Feliciano¹,Ramírez-Tirado Laura Alejandra¹,Zatarain-Barrón Zyanya Lucia¹,Cardona Andrés F.²³⁴,Díaz-García Diego¹,Yamamoto Ramos Masao¹,Mota-Vega Beatriz¹,Carmona Amir¹,Peralta Álvarez Marco Polo¹,Bautista Yolanda⁵,Aldaco Fernando⁶,Gerson Raquel⁷,Rolfo Christian⁸,Rosell Rafael⁹

Affiliation:

1. Thoracic Oncology Unit, Laboratory of Experimental Oncology, National Cancer Institute (INCan), Mexico City, Mexico

2. Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia

3. Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia

4. Molecular Oncology and Biology Systems Research Group (G-FOX), Universidad el Bosque, Bogotá, Colombia

5. Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico

6. Servicio de Oncología Médica, Centro Médico Nacional 20 de Noviembre, Mexico City, Mexico

7. Departamento de Oncología, Centro Médico ABC, Mexico City, Mexico

8. Thoracic Medical Oncology and Early Clinical Trials, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore

9. Molecular and Cellular Oncology Laboratory, Germans Trias i Pujol Research Institute and Hospital (IGTP), Barcelona, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2763865/jamaoncology_arrieta_2020_oi_200008.pdf

Reference39 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018

2. A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non–small cell lung cancer.;Pacheco;Front Oncol,2019

3. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?;Morabito;BMC Med,2018

4. Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: meta-analysis and systematic review.;Yu;Oncol Lett,2017